Background Epigenetic therapeutics such as the histone deacetylase (HDAC) inhibitor,
vorinostat, and the DNA methyltransferase (DNMT) I inhibitor, azacitidine, sensitize AML …

Purpose This randomized trial evaluated the efficacy and toxicity of sequential gemtuzumab
ozogamicin (GO) and standard chemotherapy in older patients with newly diagnosed acute …

Background Gemtuzumab ozogamicin (GO) is effective as single agent in the treatment of
acute myeloid leukemia (AML). We evaluated efficacy and safety of a chemotherapy …

Histone deacetylase inhibitors such as vorinostat enhance gemtuzumab ozogamicin efficacy
in vitro. We, therefore, investigated vorinostat+ gemtuzumab ozogamicin for adults aged 60 …

Background: In this study, the effectiveness and safety of combining gemtuzumab
ozogamicin (GO) with an abbreviated schedule of standard induction chemotherapy were …

Purpose To compare single-agent gemtuzumab ozogamicin (GO) with best supportive care
(BSC) including hydroxyurea as first-line therapy in older patients with acute myeloid …

Gemtuzumab ozogamicin (GO), an anti-CD33 monoclonal antibody conjugated to
calicheamicin, is effective as single agent in the treatment of poor risk acute myeloid …

BACKGROUND: Elderly patients with acute myeloid leukemia (AML) are generally unable to
withstand the rigors of intensive induction chemotherapy and its attendant complications …

BACKGROUND AND OBJECTIVES: Acute myeloid leukemia (AML) in the elderly is
associated with low rates of response to conventional chemotherapy and long-term survival …

We report the final results of a prospective multi‐centre trial testing the combination of
chemotherapy (fludarabine, cytosine arabinoside and idarubicin; FLAI) followed by low …